NL
DE
MatTek Life Sciences, a Boston-area tissue engineering company and a member of the BICO Group, announced today it has entered into a distribution agreement and strategic partnership with Radboudumc’s spin-off company Cell4Pharma, a company specializing in commercially available human renal cells, to distribute its products in the US as well as develop a new in vitro kidney model. “The strategic partnership with MatTek is in line with our goal to accelerate our growing global network of strategic partners. This partnership supports our mission to support human-relevant research by providing synergistic life science products and services,” said Ron Byron, CEO of Cell4Pharma. Read full article here: MatTek Enters Distribution Agreement and Strategic Partnership with Cell4Pharma (bico.com)
Related news items
Third Radboudumc Investment Day again well-attended
16 October 2023On October 12, the Radboudumc Investment Day took place for the third time. Scientists, entrepreneurs and investors from the life sciences & health sector came together in the Radboudumc Experience Center to exchange knowledge, network and talk about new collaborations.
read more
Boosting the startup ecosystem in Nijmegen!
22 June 2023TechleapNL, Radboud university, Radboudumc and the municipality of Nijmegen hosted a successful event where innovative health and hightech startups shared their view on the challenges and opportunities for the local startup ecosystem.
read more
Meet Healthy Ideas, Healthy Returns
2 June 2023Do you have a golden idea to improve healthcare, but not the resources to realize it? Discover Healthy Ideas, Healthy Returns: a Benelux-wide public-private network offering opportunities for healthcare investments and propositions, among other things.
read more
Cell4Pharma successfully closed a major funding round
25 May 2023Radboudumc spin-off Cell4Pharma is pleased to announced it has successfully closed a major funding round, marking a significant milestone in their journey towards developing ciPTEC as the leading platform to study human renal biological interaction during the preclinical stages of drug development
read moreAftermovie Investment Day 2022 and a new date for 2023!
13 December 2022Over 100 scientists, investors, and entrepreneurs came together to accelerate innovation in healthcare by creating new business opportunities and forging strong public-private partnerships.
read more
Successful matchmaking at Radboudumc Investment Day
7 October 2022On the 5th of October, over 100 scientists, investors and entrepreneurs came together at the second Radboudumc Investment Day, jointly hosted by Radboudumc, Oost NL and Briskr.
read more